Pretargeted Alpha Therapy of Disseminated Cancer combining Click Chemistry and Astatine-211

Chiara Timperanza, Holger Jan Jensen, Tom Bäck, Sture Lindegren, Emma Aneheim


To enhance targeting efficacy in the radioimmunotherapy of disseminated cancer, several pretargeting strategies have been developed. In pretargeted radioimmunotherapy, the tumor is pretargeted with a modified monoclonal antibody that has an affinity for both tumor antigens and radiolabeled carriers. In this work, we aimed to synthesize and evaluate poly-L-lysine-based effector molecules for pretargeting applications based on the tetrazine and trans-cyclooctene reaction using 211At for targeted alpha therapy and 125I as a surrogate for the imaging radionuclides 123, 124I. Poly-L-lysine in two sizes was functionalized with a prosthetic group, for the attachment of both radiohalogens, and tetrazine, to allow binding to the trans-cyclooctene-modified pretargeting agent, maintaining the structural integrity of the polymer. Radiolabeling resulted in a radiochemical yield of over 80% for astatinated poly-L-lysines and a range of 66-91% for iodinated poly-L-lysines. High specific astatine activity was achieved without affecting the stability of the radiopharmaceutical or the binding between tetrazine and transcyclooctene. Two sizes of poly-L-lysine were evaluated, which displayed similar blood clearance profiles in a pilot in vivo study. This work is a first step toward creating a pretargeting system optimized for targeted alpha therapy with 211At.

Original languageEnglish
Article number595
JournalPharmaceuticals (Basel)
Issue number4
Publication statusPublished - 15 Apr 2023


Dive into the research topics of 'Pretargeted Alpha Therapy of Disseminated Cancer combining Click Chemistry and Astatine-211'. Together they form a unique fingerprint.

Cite this